While the current PD-1/PD-L1 medications have demonstrated efficacy in the treatment of NSCLC, this pathway serves as the primary mechanism via which NSCLC tumour cells evade immune system detection [47]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.